Member Info for apps

The company didn't exit gaming and rebrand into defence.

The gaming company Guild was sold off to DCB sports and the LSE listing was no longer required.

The LSE listing then effectively became a shell vehicle.

That shell was then repositioned, renamed Cassel Capital, then renamed again to Defence Holdings — and re-capitalised under new management and mandate.

Just a quicker route to LSE listing for Defence Holdings

I seem to remember someone posting on here saying FDA have up to max. 90 days but typically a response with designation given, or request for more information is between 60-75 days. 60 days is tomorrow.

I haven't checked how accurate this is.

There’s strong buying interest today, but market makers appear to be delaying prints from bid-side trades, likely to soften the appearance of demand. The spread movement doesn’t reflect the underlying volume being taken.

Interestingly, Interactive Investor (ii) still isn’t allowing buys, which tells you how tight the market is and how carefully the clearing houses are managing access.

Once full buying access opens across brokers, the true level of demand will become clearer — and it could be significantly higher than what’s visible on-screen right now.

This RNS screams “institutional maturity”

They’re now playing on the global defence AI stage, and the market hasn’t yet priced that in.

If the presentation at Oracle AI World lands well next week, and any US coverage begins post-event, ALRT could re-rate sharply, especially with the ALRDF ticker drawing US eyes.

The statement “no longer assembling a portfolio, it is delivering one” is a strong line — meaning execution phase. The classified builds, hyperscale collaborations, and Oracle AI World invite all back that up.

Also: aligning with UK Strategic Defence Review 2025 (SDR25) and NATO interoperability = massive long-tail relevance. It ties ALRT into national policy, not just a tech fad.

Oracle AI World invitation (Las Vegas, 13–16 Oct)

Being invited to present — not just attend — means they’re being recognised in the top tier of AI infrastructure companies. Oracle’s ecosystem includes hyperscale cloud, sovereign AI architecture, and defence-grade infrastructure.

This is a big step toward partnership visibility with hyperscale and defence primes — think Lockheed, Palantir, Oracle, Microsoft, AWS etc

L2 already showing gap up but MMs are deleting their already higher price to raise the price even further.

They can see the orders stacking up and don’t have shares to sell.

Blow the doors of RNS

Bashers can try today but they won’t be heard

This is a very strong, strategic RNS — and probably the most significant one Defence Holdings (ALRT) has released so far. Here’s the breakdown and what it really means under the surface 👇

⸻

🔑 Key Positives

1. US OTC listing (Ticker: ALRDF)

This is a major credibility and liquidity move. It gives direct access to US investors, who are far more familiar with defence tech and AI plays than UK investors. It also opens the door for future dual-market valuations — and US small-cap investors often pay higher multiples for “AI + defence” stories.

💡 Expect increased volume and awareness from US retail and institutional tech funds.

2. Oracle AI World invitation (Las Vegas, 13–16 Oct)

Being invited to present — not just attend — means they’re being recognised in the top tier of AI infrastructure companies. Oracle’s ecosystem includes hyperscale cloud, sovereign AI architecture, and defence-grade infrastructure.

This is a big step toward partnership visibility with hyperscale and defence primes — think Lockheed, Palantir, Oracle, Microsoft, AWS etc.

3. Two classified AI product builds “on budget and on schedule”

That confirms real commercial traction. Most AIM-type companies talk about prototypes; this says active builds with validation milestones in Q4. That means revenue, contract continuity, and momentum.

⸻

💷 Funding Mechanism (ATM Facility)

They’ve set up an At-The-Market equity facility — this is not a discount placing.

• Shares are drip-sold into strength rather than dumped in bulk.

• Strict limits: 5% of daily or 20% of weekly volume.

• The initial 144.9M issued shares are held by Fortified, to sell gradually under pre-agreed conditions.

✅ This structure signals confidence and sophistication — it’s the same system used by US Nasdaq-listed growth firms like Palantir or NVIDIA in their early phases.

❗ Not dilution panic — it’s controlled, market-neutral capital access.

⸻

🧭 Strategic Outlook

The statement “no longer assembling a portfolio, it is delivering one” is a strong line — meaning execution phase. The classified builds, hyperscale collaborations, and Oracle AI World invite all back that up.

Also: aligning with UK Strategic Defence Review 2025 (SDR25) and NATO interoperability = massive long-tail relevance. It ties ALRT into national policy, not just a tech fad.

⸻

⚙️ Warrants

61.8M exercised, 59.8M already sold, so no overhang risk. That’s handled perfectly — smart pre-management of potential drag.

Type Idiopathic Pulmonary Fibrosis into ‘orphan designation’ on https://www.accessdata.fda.gov/scripts/opdlisting/oopd/ website.

93 FDA designations (ODD ✔️) over last 20 years for IPF and still only two approved drugs.

Tells you everything about the size of the opportunity.

FDA wants innovation here — and NFX’s inhaled route gives it a real edge.

IMHO, odds of ODD on first application are good.

Trans, yep, I agree, we don't need Pam & Derek on here but I'm new to NFX and in researching NXP002 and the significance of U.S. ODD, no harm in posting the research here. Its not to pump or sell it to newcomers, its to inform. Most people who come to this board for the first time may have no idea why U.S. ODD could be transformational for the company. The last few posts spell it out without the need to go digging.

So my next question was: why not a massive re-rate on EU ODD approval.

The EU ODD win was big strategically, but not yet financially material — and the market is waiting for proof of value conversion (or a US ODD).

⚙️ 1. The EU ODD is validation, not monetisation

Investors know ODD doesn’t equal approval or revenue — it’s a regulatory green light, not a payday.

It says: “You’re on the right track, you qualify for protection if you get to market.”

Until there’s data (efficacy in humans) or a licensing deal, the market doesn’t re-rate heavily.

💰 2. The real jackpot is the US ODD + partner interest

Big Pharma doesn’t need the EU label to pounce — they want US exclusivity (7-year market monopoly).

When the FDA grants ODD, it tends to spark real valuation change because US pricing power dwarfs Europe’s.

Many funds are effectively sitting on their hands until that announcement drops — and that’s where the rerate could come hard and fast.

🧪 3. Market psychology — biotech fatigue & microcap neglect

Nuformix is a microcap — below the radar of most institutions and algos.

The sector’s been battered for years, and traders have become numb to early regulatory wins until there’s visible cashflow or licensing activity.

Ironically, that’s why ODD-stage plays are the best asymmetric setups — all the risk is priced in, none of the optionality is.

🦅 4. What will make it move

Expect momentum once one of these hits:

✅ US ODD granted (confirmation of exclusivity moat in key market)

🤝 Licensing or JV deal (Big Pharma validation + cash)

Any of those will shift NFX from “theory” to “transaction,” and that’s when the market typically wakes up.

⚖️ Summary: The smart money knows the setup

Right now, the science and regulatory stars are aligning, but the market hasn’t caught up.

That’s why the share price looks static — but beneath the surface, it’s setting up for potential re-rating catalysts that could revalue NFX many-fold once the US ODD or first partner deal lands.

Tranilast isn’t a risky new compound — it’s a proven anti-fibrotic drug with decades of safe use behind it. Nuformix’s genius lies in repurposing it as an inhaled therapy (NXP002) for Idiopathic Pulmonary Fibrosis (IPF) — a brutal disease with few effective treatments.

👇

If NXP002 secures Orphan Drug Designation (ODD) in the US, it instantly gains 7 years of market exclusivity (10 in the EU). That’s a regulatory moat that turns an old generic into a protected billion-dollar asset.

Big Pharma loves this model — low scientific risk, known safety profile, and a locked-in monopoly window if approved. That’s exactly why they’ll be watching NFX closely. Once ODD lands, it’s not a “maybe someday” biotech — it’s a ready-made acquisition target with the kind of de-risked potential the majors pay huge money for.

Why Orphan Drug Designation (ODD) is so powerful for repurposed compounds like tranilast (NXP002).

🔬 1. How “proven” is tranilast?

Tranilast isn’t an experimental molecule — it’s a well-known anti-fibrotic and anti-inflammatory drug that’s been approved and marketed in Japan and South Korea for decades (originally for allergic and fibrotic conditions such as asthma and keloids).

Its safety profile is already well-established — this is gold dust in drug development because it de-risks the early clinical phases.

What’s new is not the molecule, but how it’s delivered (inhaled) and what disease it’s aimed at (idiopathic pulmonary fibrosis – IPF).

So Nuformix isn’t inventing tranilast — it’s reinventing how it’s used.

This means:

✅ Preclinical toxicology risk → very low

✅ Mechanistic rationale → already supported by fibrosis models

🧱 2. Why ODD is a “massive winner” for repurposed drugs

Because you can’t patent the old molecule again, the only way to build commercial defensibility is through:

New formulation patents (e.g. inhaled version, crystalline form, salts, or delivery method), and

Regulatory exclusivity — which is exactly what ODD provides.

So in this case, ODD gives Nuformix 7 years (US) or 10 years (EU) of market exclusivity even though tranilast itself is old and off-patent.

That exclusivity prevents another company from marketing the same drug for the same indication (IPF) during that period — effectively creating a monopoly if the drug is approved.

And that’s the magic of ODD:

💡 It turns a scientifically low-risk, low-cost repurposing project into a high-value, protected commercial asset.

It’s why many small biotechs hunt for old drugs with new uses — if they can get ODD, they suddenly have pharma-grade defensibility without the billion-dollar R&D bill.

💰 3. The leverage point

If NXP002 shows clear efficacy in IPF:

The clinical risk is modest (because the molecule is understood).

The regulatory risk is moderate (ODD gives an accelerated path).

The commercial upside is huge (7–10 years of exclusivity, premium pricing for a rare, severe disease).

That’s why the market sees ODD as a massive inflection point.

Without it — NXP002 is “just” a clever reformulation of an old generic.

With it — it’s a protected, potentially billion-dollar orphan therapy.

Defence Holdings OTC listing was still GULDF from original Guild Esports listing.

Ticker has been updated to ALRDF on OTC today.

NMS cutting from 1,000,000 to 500,000 while the spread has tightened right up. Controlled management of a thin book.

MMs clearly keeping this under close control, matching orders in smaller clips to stop a rush either way. When liquidity gets this tight, it’s often the calm before momentum shifts hard.

Institutions still restricting buys (ii & AJB) says plenty — they don’t want retail loading before the next development lands.

With limited free float and tighter trade sizes, every blue print counts. The book feels primed — once the gate opens, there won’t be much time to react.

Tight spread, reduced NMS, controlled flow — classic setup before the break. Holders looking solid.

Keep an eye on NFX, MMs have also had a tough week there too.

Spread tightening up again on a steady stream of blue — the drift higher feels controlled, not forced.

£20k of buys through the ask at 09:13 gave NFX the lift, and the £11k sell at 10:34 the tick down.

Overall sentiment’s solid; volume’s clean, and the tape suggests accumulation rather than churn.

Hopefully no “Pam and Derek” games today — happy to see Pam, Derek can take the day off 😉

Feels like MMs are quietly positioning ahead of news — scooping cheap stock to manage the book when the RNS drops. Once the lid comes off, it won’t take much volume to move this fast.

Expecting mid-0.3s consolidation before the next push — any sniff of positive news and this could gap straight to 0.6+ in a single session.

Tight spreads, thin supply, strong hands forming — not one to be chasing after the fact.

PnD (Pat n Derek) 🤔 have left the building. It livened things up for a while.

Very few x,xxx,xxx trades went through to create todays 23% uplift.

Approx two thirds of the way to an answer from FDA, like the last week or so, the next few weeks are going to be volatile in the hope of partnership announcment.

When only one MM on bid (PEEL) with 2m

Who is hoovering up stock? Derek?

Shame to see their profile gone, it was fun while it lasted.

You need a different broker. ii will take 5,000,000 at full bid without NT